CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancer. The company’s technology is designed to expand the capabilities of conventional T cells by combining targeted tumor-cell recognition and killing with phagocytic activity, potentially enabling immune cells to engulf and eliminate malignant cells.

CERo’s lead product candidate is CER-1236, an engineered T-cell therapy directed at CD123, a cell-surface protein expressed on several hematologic malignancies, including acute myeloid leukemia. The company has been advancing CER-1236 toward clinical development and is evaluating its potential in patients with relapsed or refractory blood cancers. Its broader research programs are focused on applying the company’s engineered-cell platform to additional oncology targets.

The company was established to develop next-generation cellular immunotherapies and became publicly traded through a business combination with Phoenix Biotech Acquisition Corp. in 2024. CERo Therapeutics is focused primarily on research, development and clinical testing rather than commercial product sales, and its therapies are not yet broadly available.

Key Stats

• Today's Range: $0.01 to $0.0124
• 50-Day Range: $0.0080 to $0.0158
• 52-Week Range: $0.01 to $5.66
• Volume: 422,382 shs
• Average Volume: 659,028 shs
• Market Capitalization: $859.57 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Reduce

CERo Therapeutics Stock Analysis - MarketRank™

CERo Therapeutics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

CERo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

CERo Therapeutics has a consensus price target of $30.00, representing about 249,900.0% upside from its current price of $0.01.

Amount of Analyst Coverage

CERo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CERO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CERo Therapeutics does not currently pay a dividend.

Dividend Growth

CERo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for CERO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CERo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.36% of the stock of CERo Therapeutics is held by insiders.

Percentage Held by Institutions

29.64% of the stock of CERo Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/22/2025
• Today: 9/24/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CIK: 1870404
• Web: www.cero.bio
• Phone: 215-731-9450
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CERo Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +249,900.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($41.98) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 71,631,000
• Free Float: 1,052,000
• Market Cap: $859.57 thousand
• Optionable: N/A
• Beta: 0.19